Skip to content
← All supplements
Omega-3
Essential Brain Fuel

Omega-3

EPA & DHA (Fish Oil)

Key Benefits

Brain Function

DHA comprises 40% of brain polyunsaturated fats, supporting cognitive function, memory, and neuroplasticity.

Cardiovascular Health

Reduces triglycerides, improves arterial function, and supports healthy blood pressure.

Anti-Inflammatory

EPA produces anti-inflammatory eicosanoids, reducing chronic inflammation throughout the body.

Mood Support

Supports mental health and may reduce symptoms of depression, particularly when EPA-dominant.

auto_awesome

Activation Synergies

recommended Vitamin E

Vitamin E protects omega-3 fatty acids from oxidation, preserving their beneficial effects and preventing rancidity.

optional CoQ10

CoQ10 enhances mitochondrial function alongside omega-3s, supporting cardiovascular and energy benefits.

Recommended Dosage

medical_services
1000-2000 mg (EPA+DHA) / daily

Look for EPA+DHA combined content (not just "fish oil" weight). Higher EPA for mood/inflammation, higher DHA for cognitive support. Take with meals to reduce fishy aftertaste.

warning

Deficiency Indicators

  • Dry, scaly skin
  • Brain fog or poor concentration
  • Joint pain or stiffness
  • Mood issues or depression
  • Poor cardiovascular health
verified

Scientific Citations

NIH Office of Dietary Supplements open_in_new

Omega-3 Fatty Acids Fact Sheet

Examine.com open_in_new

Fish Oil: Research Summary

Forms & absorption

science

Not all forms absorb equally — these are ordered best-absorbed first.

  • Triglyceride (rTG) form trending_up Well absorbed · best for Getting the most EPA/DHA per capsule

    Re-esterified triglyceride form — absorbed better than ethyl ester.

  • Phospholipid (krill oil) trending_up Well absorbed

    Well absorbed, but usually carries less EPA/DHA per capsule.

  • Ethyl ester (EE) trending_flat Moderate · best for Budget

    Common and cheaper; absorbed noticeably better when taken with a fatty meal.

Absorption varies between people; informational only, not medical advice.

Research & Sources

What the evidence says — with links to the original studies

Consensus: controversial

There is high-certainty evidence that long-chain omega-3 (EPA+DHA) lowers blood triglycerides in a dose-dependent way (~15% at supplement doses, ~30% at prescription 4 g/day), and this is recognized by the NIH ODS, the American Heart Association, and EFSA. However, evidence that omega-3 supplements prevent cardiovascular events or death in the general population is mixed and largely null (VITAL, ASCEND, Cochrane 2020), with a clear benefit shown only in one high-risk EPA-only trial (REDUCE-IT). For mood, meta-analytic evidence favors EPA-predominant formulations over DHA. Bioavailability differs by chemical form (rTG and natural triglyceride absorb better than ethyl ester), though dose-matched plasma levels of krill and fish oil are broadly comparable.

check_circle

Supporting Evidence

Government fact sheet NIH Office of Dietary Supplements (ODS)

States EPA/DHA lower triglycerides and may reduce some CV endpoints, with stronger evidence in people with existing coronary heart disease than in healthy adults.

RCT New England Journal of Medicine, 2019

8,179 statin-treated high-risk patients; 4 g/day icosapent ethyl (EPA-only ethyl ester) cut major adverse CV events by ~25% (HR 0.75) vs placebo. The strongest positive CV-outcome trial.

Professional-society science advisory Circulation (AHA), 2019

Concludes prescription EPA+DHA or EPA-only at 4 g/day reduces triglycerides by 20-30%+ and is an effective, safe option as monotherapy or adjunct.

Systematic review / meta-analysis Mayo Clinic Proceedings, 2020

40 trials; found a dose-dependent protective effect for MI and CVD events (~9% MI risk reduction per additional gram/day EPA+DHA); supports 1,000-2,000 mg/day.

Systematic review / meta-analysis Translational Psychiatry, 2019

EPA-pure and EPA-major formulations improved depression, while DHA-pure/DHA-major did not; optimal signal at >=60% EPA and <=1 g/day.

RCT PLOS ONE, 2023

16-week RCT: a >95% re-esterified triglyceride (rTG) product produced significantly greater erythrocyte EPA/DHA incorporation than a <70% rTG preparation.

info

Opposing / Critical Views

Cochrane systematic review Cochrane Database of Systematic Reviews, 2020 (CD003177.pub5)

86 trials, 162,796 participants: little or no effect of EPA/DHA on all-cause mortality or major cardiovascular events (moderate/high certainty); only a small reduction in coronary deaths/events (low certainty) plus high-certainty triglyceride lowering.

RCT New England Journal of Medicine, 2019

25,871 general-population adults; 1 g/day (460 mg EPA + 380 mg DHA) did not reduce major CV events (HR 0.92) or cancer; a secondary signal for total MI (HR 0.72) only.

RCT New England Journal of Medicine, 2018

15,480 people with diabetes and no known CVD; 840 mg/day omega-3 showed no benefit on serious vascular events (8.9% vs 9.2%, p=0.55).

Educational summary of published research — not medical advice. Consult a qualified professional before supplementing.

groups

Have You Tried This?

Join our collective laboratory. Share your experience level with this topic and help others gauge the journey.

Based on .

No one has shared yet. Be the first to place a pin on the map.

check_circle You marked yourself as .

Status: In Your Stack Status: Not in Stack